Becker DA, et al. - In this retrospective cohort study of patients with surgical stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, researchers assessed the tolerability and toxicity of an outpatient IP chemotherapy regimen consisting of docetaxel 75 mg/m² IV and cisplatin 75 mg/m² IP day 1 followed by paclitaxel 60 mg/m² IP day 8 every 21 days administered to 60 patients. An improved tolerability profile was seen with this docetaxel-based IP chemotherapy regimen vs GOG172. Neutropenia (47%), gastrointestinal (28%), and anemia (25%) were most common toxicities documented. No IP port complications were noted in the majority of patients (85%). Also, 30% of cases needed dose delay or reduction. Complete response was achieved for 88% and 25.5 months and 56.8 months were the median progression-free survival (PFS) and overall survival (OS), respectively, for all patients. They observed median PFS of 22.1 months and median OS of 56.8 months for the 44 patients with stage III disease.